Vical Inc. (NASDAQ:VICL) said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is a plasmid DNA vaccine that encodes the HSV-2 glycoprotein D...

Vical Inc. (NASDAQ:VICL) sank $0.43 (26%) to $1.20 on Monday after the company said it will discontinue development of VCL-HB01 after the HSV-2 vaccine missed the primary endpoint in a Phase II trial. VCL-HB01 is...

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the international Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. The...

Astellas Pharma Inc. (Tokyo:4503) and partner Vical Inc. (NASDAQ:VICL) said cytomegalovirus (CMV) vaccine ASP0113 missed the primary and secondary endpoints in the Phase III HELIOS trial in CMV-seropositive allogeneic stem cell transplant recipients. Vical sank...

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...

The fallout of Sanofi’s dengue vaccine debacle has researchers scrambling to rationalize whether competitor products will fall afoul of the same effects, and whether other, related fields should change course. The early upshot is that...

In April, Vical Inc. (NASDAQ:VICL) completed enrollment of 225 adults with symptomatic genital herpes simplex virus type 2 (HSV-2) infection in a Phase II trial evaluating 1 mL intramuscular VCL-HB01 (HSV-2 vaccine, Vaxfectin-formulated plasmid DNA...

Merck & Co. Inc. (NYSE:MRK) said it will submit applications in the U.S. and EU this year for letermovir (MK-8228) to prevent cytomegalovirus (CMV) infection in CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplantation...

Vical began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. Vical Inc. (NASDAQ:VICL), San Diego, Calif.   Product: Herpes simplex...